Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: A Southwest Oncology Group trial

Journal of Cancer Research and Clinical Oncology

Volumn 125, Issue 5, 1999, Pages 292-296

  Margolin, Kim A ^a   Liu, P Y ^b   Unger, Joseph M ^b   Fletcher, William S ^c   Flaherty, Lawrence E ^d   Urba, Walter J ^e   Hersh, Evan M ^f   Hutchins, Laura E ^g   Sosman, Jeffrey A ⁱ   Smith, John W ^e   Weiss, Geoffrey R ⁱ   Sondak, Vernon K ^h  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Columbia River CCOP ^*  (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ NONE

Author keywords

Biochemotherapy; Interferon; Melanoma

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; TAMOXIFEN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MIXTURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032977509     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050276     Document Type: Article

References (23)

1. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C, Aronson FR (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12:1553-1560
2. Bajetta E, Negretti E, Giannotti B, Brogelli L, Brunelli I, Sertoli MR, Bernengo MG, Sofra MC, Maifredi G, Zumiani G, Comella G, Buzzoni R, Di Leo A, Criscuolo D, Massimini G, Cascinelli N (1990) Phase II study of interferon α-2a and dacarbazine in advanced melanoma. Am J Clin Oncol (CCT) 13:405-409
3. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG, Menichetti ET, Palmeri S, Russo A, Cristofolinio M, Erbazzi A, Fowst C, Criscuolo D, Bufalino R, Zilembo N, Cascinelli N (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811
4. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408
5. Falkson CI, Ibrahim J, Kirkwood JM, et al. (1996) A randomized phase III trial of dacarbazine (DTIC) versus DTIC - interferon α-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: an ECOG trial. Proc Am Soc Clin Oncol 15, 1350:435
6. Falkson CI, Ibrahim J, Kirkwood, JM, et al (1998) Phase III Trial of Dacarbazine versus Dacarbazine with Interferon α-2b versus Dacarbazine with Tamoxifen versus Dacarbazine with Interferon α2b and Tamoxifen in Patients with Metastatic Malignant Melanoma: An Eastern Cooperative Oncology Group Study J Clin Oncol 16: 1743-1751
7. Flaherty LE, Liu PY, Mitchell MS, et al. (1996) The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. Am J Clin Oncol 19:108-113
8. Flaherty L, Liu PY, Unger J, Sondak V (1997) Comparison of patient characteristics and outcome between a single institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol (CC) 20:600-604
9. Fletcher WS, Daniels SD, Sondak VK, et al. (1993) Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. Am J Clin Oncol 16:359-362
10. Green SJ, Dahlberg S (1992) Planned versus attained design in phase II clinical trials. Stat Med 11:853-862
11. Green SJ, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253
12. Hersey P, McLeod GRC, Thomson DB (1991) Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: Long-term follow-up of two phase II studies. Br J Haematol 79:60-66
13. Keilholz U, Goey SH, Punt C JA, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont MM (1997) Interfon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588
14. Khayat D, Borel C, Tourani JM, et al. (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180
15. Kirkwood JM, Hunt-Strawderman M, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17
16. Legha SS, Ring S, Papadopoulos N, et al. (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64:2024-2029
17. Legha SS, Ring S, Eton O, et al. (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759
18. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D (1989) The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295
19. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmuno-therapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343
20. Sondak VK, Margolin KA (1999) Melanoma and other skin cancers. In: Pazdur R, et al. (eds) Cancer Management: A Multidisciplinary Approach 3rd Ed, PRR, Huntington, NY, In Press
21. Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, Olver IN, Kefford RF, Lowenthal RM, Beadle GF, et al. (1993) Interferon α-2a does not improve response or survival when combined with dacarbazine (DTIC) in metastatic melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 3:133-138
22. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473-3486
23. Welander CE (1987) Overview of Preclinical and Clinical Studies of Interferon Alfa-2b in combination with Cytoxic Drugs. Invest New Drugs 5:S47-S59